Answers are grounded in this paper and cite their sources.
Donor lymphocyte infusion (DLI) is an established and potentially curative immune therapy for relapsed leukemia after hematopoietic stem cell transplant (HSCT). Herein, we describe the utility of DLI as a tractable model system to glean fresh insights into understanding and predicting effective anti-leukemia immunity.
No takes yet. Share an insight, caveat, or question.
Bachireddy et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: